Find Clinical Trials

Inclusion criteria: For inclusion in the study, participants must fulfill all the following criteria: 1. voluntary and competent to consent to study, 2. Adults aged 18 years old or older, 3. can speak and read English, 4. primary and/or predominant diagnosis of major depressive episode without psychotic features in the current episode (confirmed by a Mini-International Neuropsychiatric Interview), 5. depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant trial in the current depressive episode, 6. moderate symptoms in the current depressive episode as indexed by a score of at least 15 on the Grid 17-item Hamilton Rating Scale for Depression (Grid HRSD-17), 7. have been referred to rTMS treatment by their treating physician, and took a free and informed decision to follow this treatment, 8. are able to adhere to treatment schedule, 9. have stable psychotropic medications (including prescribed cannabis) or psychotherapy regimen for at least four weeks prior to entering the trial, 10. have an education-adjusted score of ≥ 24 at the Mini-Mental State Evaluation (MMSE) if they are aged ≥ 65. Exclusion criteria: Participants fulfilling any of the following criteria will be excluded from the study: 1. diagnosis of bipolar I or II disorder, based on the DSM-5 criteria 2. current or past (\< 3 months) substance (excluding caffeine or nicotine) or alcohol use disorder, as defined in DSM-5 criteria. Based on the DSM-5 criteria, mild cannabis or alcohol use disorder would be permissible in the past 3 months, moderate to severe would be an exclusion. 3. current use of illegal substances or cannabis (unless medical use, see note below), confirmed by urine drug screen 4. have a concomitant major unstable medical or neurologic illness (e.g. uncontrolled diabetes or renal dysfunction), 5. organic cause to the depressive symptoms (e.g. thyroid dysfunctions), as ruled out by the referring physician 6. acute suicidality or threat to life from self-neglect, 7. are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment (pregnancy will be assessed by a urine test), 8. have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker), 9. unwilling to maintain current antidepressant regimen, 10. are taking more than 1 mg of lorazepam per day or equivalent, 11. any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study, 12. any contraindications for MRI 13. have failed a course of ECT within the current depressive episode due to the lower likelihood of response to rTMS (if they have had failed ECT in the past, this does not exclude them)

Inclusion Criteria: * Female participants only, aged 18 or above * Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best option for their next treatment based on response to and/or tolerability of prior therapy. * Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP. * ECOG/WHO performance status 0 to 1, and a minimum life expectancy of 12 weeks. * At least one lesion that is measurable and/or non-measurable, as per RECIST v1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment. Exclusion Criteria: * Intervention with any of the following: * Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs for the treatment of advanced cancer from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is shorter) of the first dose of IMP (21 days for myelosuppressive therapies) other than GnRHa (eg, goserelin) and bone-stabilizing agents (eg, zoledronic acid, denosumab). * Any prescription or non-prescription drugs or other products, including herbal products, known to be moderate or strong inhibitors/inducers of CYP3A4/5 which cannot be discontinued prior to first dose of IMP and withheld throughout the study until 2 weeks after the last dose of study drug. * Drugs that have a known risk of Torsades de Pointes. * Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP. * Major surgical procedure or significant traumatic injury, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anesthesia during the study. * Any unresolved toxicities of Grade ≥ 2 from prior anti-cancer therapy (with the exception of alopecia). Participants with stable ≤ Grade 2 neuropathy are eligible. * Presence of life-threatening metastatic visceral disease, as judged by the Investigator, uncontrolled CNS metastatic disease. Participants with spinal cord compression and/or brain metastases may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off steroids for at least 4 weeks prior to start of IMP. * Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or eg, infection requiring IV antibiotic therapy, or active infection including hepatitis B, hepatitis C, and HIV (active viral infection is defined as requiring antiviral therapy; screening for chronic conditions is not required). * Any of the following cardiac criteria: * Mean resting QTcF \> 470 msec obtained from a triplicate ECG * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Participants with controlled atrial fibrillation can be enrolled. * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death at \< 40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease. * LVEF \< 50%, and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥ 2, cerebrovascular accident, or transient ischemic attack. * Uncontrolled hypertension. * Inadequate bone marrow reserve or organ function as demonstrated by relevant laboratory values: * Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of IMP(s). * History of hypersensitivity to active or inactive excipients of AZD8421 or drugs with a similar chemical structure or class to AZD8421. * Previous treatment with AZD8421 or with any CDK2-selective inhibitor, or protein kinase membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 1 (PKMYT1) inhibitor, or WEE1 inhibitor. * Currently pregnant (confirmed with positive pregnancy test), breast feeding, or planning to become pregnant. Participants of childbearing potential must agree to use one highly effective contraceptive measure.

Inclusion Criteria: To be eligible, participants must be: * enrolled in VA primary care through the local VA site * report clinically significant psychological distress as measured in at least one of three areas: * PTSD operationalized by 30 on the PCL-5 plus endorsing a criteria A stressor * depression operationalized as 10 on the PHQ-9 * anxiety operationalized by 10 on the GAD-7 Exclusion Criteria: Exclusion criteria are minimized to allow inclusion of any primary care patients with psychological distress that would normally receive treatment in primary care. Patients will be excluded if they demonstrate symptoms that would not allow them to actively participate in the interventions: * gross cognitive impairment * suicide attempt or desire to commit suicide in the last month To allow the study to isolate the effects of the intervention and ensure patient treatment preferences are honored, patients will be excluded if they: * had a psychotherapy appointment outside of primary care within the last month and have future appointment scheduled * had a change in psychiatric medication outside of VHA primary care in the last 2 months * voice a preference to be directly referred to specialty mental health care Veterans with mild TBI, and alcohol/ substance use disorders will not be excluded because these problems commonly co-occur with psychological distress, and individuals with these conditions have previously benefited from mindfulness and problem-solving training. Patients who receive Primary Care Mental Health Integration (PCMHI) services will not be excluded as this is part of the usual primary care services that all Veterans receive.

Inclusion Criteria: 1. Patient receiving HIV care in Khayelitsha (confirmed by medical record) 2. Currently prescribed TDF-based ART, with recent difficulties with ART adherence (self-reported in past 30 days / confirmed by pharmacy refill data) 3. Mild, moderate, or severe food insecurity (measured by HFIAS categories) AND ≥1 of the following: * Clinically significant depressive symptoms (CES-D ≥ 16) * Clinically significant post-traumatic stress symptoms (SPAN ≥ 5) 4. 18 years of age or older Exclusion Criteria: 1. Unable or unwilling to provide informed consent 2. In the past year: received CBT for depression or PTSD, or received supplemental food parcels or nutritional counseling 3. Current untreated or undertreated serious mental health issue that would interfere with participation

Inclusion Criteria: 1. Female patients with breast cancer aged ≥ 20 years and ≤ 80 years, with informed consent and meeting the treatment standard of neoadjuvant chemotherapy scheme. 2. Patients who plan to receive neoadjuvant chemotherapy based on anthracycline drugs (such as erythromycin, doxorubicin, epirubicin, pyranomycin, idabicin, pentorubicin, and mitoxantrone). 3. No treatment for breast cancer before enrollment, such as chemotherapy, targeted therapy and endocrine therapy. 4. All patients underwent coarse needle biopsy of breast tumors (axillary lymph node biopsy is required for suspected axillary lymph node metastasis) to determine the status of ER, PR, HER-2, and Ki-67. 5. All patients have normal lung function, liver and kidney function. Exclusion Criteria: 1. Cases that do not cooperate and are unwilling to sign informed consent forms. 2. Antitumor therapy, hormone replacement therapy and other breast cancer related treatments were performed before enrollment. 3. Merge any other malignant tumors. 4. Patients with poor image quality in echocardiography. 5. Continuous atrial fibrillation and severe arrhythmia affect ultrasound data collection and analysis. 6. Patients with active infections, a history of HIV, or chronic hepatitis B or C. 7. Patients with abnormal lung function or liver and kidney function. 8. Patients with hemorrhagic diseases. 9. Patients taking other heart protection traditional Chinese patent medicines and simple preparations. 10. Participated in other clinical researchers in the past 3 months.

Inclusion Criteria: * For Parts A, B, C, E, and F: Overtly healthy males or females as determined by medical history and physical examination * For Parts A, B, C, E, and F: Have a screening body mass index (BMI) in the range of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening * For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China * For Part D, participants must have a stable dose of medications within the past 3 months prior to screening * For Part D, obesity BMI in the range of 30 to 40 kg/m², inclusive, with a waist circumference of at least 102 centimeter (cm) for men and at least 89 cm for women for participants of US sites only. For participants of Singaporean, South Asian, Japanese, and/or Chinese Origin at sites outside the US, the BMI range is 27 to 40 kg/m2 and the waist circumference is at least 90 cm for men and at least 80 cm for women * For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan * Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential * For Part G, have a screening BMI in the range of 18.5 to 40 kg/m², inclusive, with no significant weight gain or loss in the past 3 months prior to screening * For Part G, participants have a decreased estimated glomerular filtration rate (eGFR) * For Parts D and G, participants are allowed to have stable background treatment for hypertension, type 2 diabetes mellitus (on oral drug therapy and/or long-acting insulin), dyslipidemia (on statin therapy) and/or hypothyroidism as determined by the investigator * For Part G, Participants should be on a stable dose of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker Exclusion Criteria: * Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders * Have known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation * Have blood pressure and/or pulse rate constituting a risk as determined by the investigator * Have a systolic blood pressure (BP) of less than 100 millimeters of mercury (mmHg) * Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position * For US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study * For Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening * Consume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine * Have alcohol intake that exceeds recommended alcohol consumption limits per local regulation or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge * For Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat) * For Parts D and G, has concurrent or anticipated use of long-acting nitrates or nitric oxide (NO) donors * For Part D, has current use of more than 3 mechanism of actions for treatment of hypertension * For Part G, has previous or current diagnosis of primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasm antibody-associated vasculitis

Inclusion Criteria: * \> 3 months post-kidney transplant * On style immunosuppressive medication * Without evidence of active infection/ inflammatory conditions * Estimated glomerular filtration rate \> 45ml/min/1.73 m\^2 * English speaking * Reliable internet access Exclusion Criteria: * Acute/ chronic allograft rejection * History of non-compliance * Advance heart failure * Liver disease * Pregnancy * Malignancy * Chronic Infection * Currently following a plant-based diet

Inclusion Criteria: * Patients diagnosed with a chronic medical condition requiring regular treatment, i.e., asthma * Ages 12-18 * English fluency for patient and caregiver Exclusion Criteria: * Diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review * Diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review

Inclusion Criteria: * had preeclampsia in the past 5 years, * 18 years or older Exclusion criteria: * current daily aspirin use, * skin diseases, * current tobacco or nicotine use (including vaping), * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * currently pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs, * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).

Inclusion Criteria: 1. Age: 18-45 years old; equal numbers of men and women 2. Body mass index (BMI): 27.5-34.9 kg/m2 3. Sleep Habits: habitual self-reported average total sleep time (TST) \<6.5 hours per night for prior 6 months Exclusion Criteria: 1. Clinically diagnosed sleep disorder or major psychiatric illness 2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease) 3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5% 4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications. 5. Cancer that has been in remission less than 5 years 6. Pregnant/nursing, experiencing menopause or post-menopausal 7. Shift-work: current or history of within last year 8. Weight change: \>10% of body weight over prior six months 9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program 10. Currently smoking 11. Alcohol intake\>14 drinks per week or \>3 drinks per day

Inclusion Criteria: * Adults aged 18 years and older with a diagnosis of asthma by a respirologist. They must have severe disease defined by GINA severity classification. Participants must have access to a smartphone or internet browser to allow access to study content. Exclusion Criteria: * Exclusion criteria include comorbid cardiopulmonary or musculoskeletal conditions that may impact exercise tolerance in accordance with the American Thoracic Society CPET guidelines

Inclusion Criteria: Patients voluntarily participated in the study, signed the informed consent, and had good compliance; Female patients aged 18-70; TNBC confirmed by histology or cytology. Triple negative is defined as \<1% expression of estrogen receptor (ER) and progesterone receptor (PR), and negative in situ hybridization expression of human epidermal growth factor receptor 2 (HER2). Unresectable locally advanced or metastatic TNBC failed or relapsed after treatment with at least one line of standard chemotherapy regimens (taxanes and/or anthracyclines); Patients should have at least one measurable lesion (RECIST 1.1); ECOG PS 0 or 1; Expected survival ≥12 weeks; Blood test (without blood transfusion within 14 days) 1. Neutrophil absolute value ≥1.5×109/L, platelet ≥100×109/L, hemoglobin concentration ≥9g/dL); 2. Liver function test (aspartate aminotransferase and glutamic aminotransferase ≤2.5×ULN, bilirubin ≤1.5×ULN; In the presence of liver metastasis, AST and ALT≤5×ULN); 3. Renal function (serum creatinine ≤1.5×ULN, or creatinine clearance (CCr)≥60ml/min); 4. Coagulation, International standardized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thrombin time (APTT) ≤1.5×ULN; 5. Thyroid function, thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If abnormal, FT3 and FT4 levels should be examined, and normal FT3 and FT4 levels can be included. Women of reproductive age must undergo a negative serum pregnancy test within 14 days prior to treatment and be willing to use medically approved effective birth control (e.g., intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last study drug use. Exclusion Criteria: During the first 4 weeks of treatment, receive the following treatments: including but not limited to surgery, chemotherapy, radical radiotherapy, biotargeted therapy, immunotherapy, and other investigational drugs; Previous treatment with anti-VEGF /VEGFR targeting drugs, such as Bevacizumab; Or have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or synergistic inhibition of T cell receptors in response to another stimulus (including but not limited to CTLA-4, OX-40, LAG-3, CD137, etc.); Immunosuppressive drugs have been administered in the 14 days prior to initiation of treatment, but do not include nasal and inhaled corticosteroid hormones or physiological doses of systemic steroid hormones (i.e., the daily dose of prednisolone does not exceed 10 mg or the equivalent physiological dose of another corticosteroid); History of any active autoimmune disease or autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or asthma may have complete remission in childhood and do not currently require medical intervention, or have a history of allotransplantation or allohematopoietic stem cell transplantation); Have high blood pressure that is not well controlled by antihypertensive medications (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) Urine routine indicated urine protein ≥2+, and 24 hours urine protein quantity \>1.0g; Obvious clinical bleeding symptoms or obvious bleeding tendency (bleeding \> 30 mL within 3 months, hematemesis, black feces, blood in stool), hemoptysis (fresh blood \> 5 mL within 4 weeks) within 3 months prior to treatment. Or treatment of venous/venous thrombosis events occurring within the preceding 6 months, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) is required; Active heart disease, including myocardial infarction, severe/unstable angina, occurs 6 months before treatment. Left ventricular ejection fraction \< 50% by echocardiography and poor arrhythmia control (including QTcF interval,\> 470 ms in women); The patient has had other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the previous 3 years or at the same time. Known allergy to the study drug or any of its excipients, or severe allergic reaction to other monoclonal antibodies; Active or uncontrolled severe infection; 1. Known human immunodeficiency virus (HIV) infection; 2. A known history of clinically significant liver disease, including viral hepatitis \[active HBV infection, i.e., HBV DNA positive (\>1×104 copies /mL or \>2000 IU/ml) must be excluded for a known hepatitis B virus (HBV) carrier; 3. Known hepatitis C virus infection (HCV) and HCV RNA positive (\>1×103 copies /mL), or other hepatitis, cirrhosis\]; Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, the patient has a medical condition or condition that is reasonably suspected to be unsuitable for the use of the study drug (such as the presence of epileptic seizures requiring treatment), or which would interfere with the interpretation of the study results, or place the patient at high risk; The patients considered by the investigators to be unsuitable for inclusion in this study.

Inclusion Criteria: * Central or peripheral neuropathic pain * Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale * Pain present on a daily or near-daily basis (at least 4 days a week) * Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain * Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study. * Patient with a depressive episode characterized according to DSM V criteria * Indication for motor cortex rTMS by a neurologist * Patient can be followed for the entire duration of the study * Patient having received informed consent to participate in the study, and having co-signed a consent form with the investigator * Member or beneficiary of a social security scheme Exclusion Criteria: * Industrial accident or litigation * Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia) * Drug or psychoactive substance abuse * Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease) * Presence of other pain more severe than that justifying inclusion * Patient unable to understand informed consent * Patient unwilling or unable to stop treatments prohibited during the study * Patient participating in another research protocol involving a drug within the 30 days prior to inclusion * Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard) * Minor patient

Inclusion Criteria: * Permanent residents of the surveyed village (residing for more than six months each year). * Age between 35 and 74 years old. Exclusion Criteria: * Individuals with severe mental disorders or communication barriers. * Individuals planning to move out of the village within the next year. * Expected life expectancy of less than one year. * Pregnant or lactating individuals. * Individuals who are currently away (i.e. hospitalized, or residing elsewhere) so that cannot participate in the survey.

Inclusion Criteria: * Patients with inflammatory breast cancer * Clinical complete response after neoadjuvant chemiotherapy * Targeted tumor * Written informed consent Exclusion Criteria: * Metastasis * Progression disease * Recurrent disease * Contraindications to adjuvant radiation therapy

Inclusion Criteria: * Aged 40 years or older * Body mass index \<50 kg/m2 * Have access to an Apple or Android cellphone with Bluetooth. * Have type 2 diabetes or be at risk for type 2 diabetes (defined as self-report of pre-diabetes, a recent (within 12 months) measure of HbA1c between 5.7 and 6.4%, waist circumference (WC) that is BMI specific; for women: BMI \>= 18.5-24.9, WC \>= 80cm; BMI \>= 25-29.9, WC \>= 90cm; BMI \>= 30-34.9, WC \>= 105cm; BMI \>= 35+, WC \>= 115cm; for men: BMI \>= 18.5-24.9, WC \>= 90cm; BMI \>= 25-29.9, WC \>= 100cm; BMI \>= 30-34.9, WC \>= 110cm; BMI \>= 35+, WC \>= 125cm. Exclusion Criteria: * Individuals with type 2 diabetes will be excluded if: (1) currently on \>2 monotherapies for diabetes, (2) have had diabetes therapy medication or dosage changes \<3 months, (3) self-reported hemoglobin A1c \>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas * The following exclusion criteria applies to all potential participants: 1. History of or referral for bariatric surgery 2. Weight loss \>3% in the last 3 months 3. Taking antiobesity (weight loss) medications 4. Body weight \>390lbs 5. Diagnosed with severe cognitive disorder that precludes them from giving consent 6. Inability or unwillingness to change their eating window to follow those prescribed in the study 7. Currently consistently eating during \<11.5 hour period . 8. Physician-diagnosed eating disorder 9. Having a pacemaker or receiving dialysis. 10. Not having access to a Lifelabs location.

Inclusion Criteria: * Adult patients aged 18-100 years old * Patient receives care at a participating primary care clinic and has been seen in the last year * Patient has high BP, defined as an average of 4 BPs \> 140 systolic or \> 90 diastolic (clinic) or \> 135 OR \> 85 (home) * Patient is enrolled in online health portal * Patient can communicate in English * Patient has been recommended by their physician who thinks the patient would benefit from a home blood pressure monitoring program. Exclusion Criteria: * Patient is pregnant at the time of consent * Patient who, in the opinion of the primary care clinician, has severe cognitive impairment * Patient is on hospice care and/or has a life expectancy of less than 2 years * Patient has end stage renal disease * Patient for whom tight blood pressure control presents a greater risk, such as those with a history of adverse events from hypertension treatment (falls, dizziness, electrolyte disturbances, hypotension, active heart failure) * Patient has any other disease or disorder that in the opinion of the investigator or the patient's primary care clinician, could put participants at risk and affect trial results, or hinder participation will exclude them from participating

Inclusion Criteria: * Women who are 18 years of age or older, do not have communication problems, have and can use a smartphone, do not have internet problems to participate in group sessions, volunteer to participate in the study, receive chemotherapy at least once a month and will continue to receive chemotherapy during the study. Women with stage 1 and stage 2 breast cancer, women with primary and secondary education, women within the first year of treatment in terms of the number of cycles, women with a score of 8 or more on the Hospital anxiety and depression scale (0-7 points are normal, 8- A score of 10 is borderline, 11 and above indicates abnormality). Exclusion Criteria: * Women who did not meet the inclusion criteria, refused to participate in the study, and participated in less than 80% of the research practices (It is recommended to participate in at least 6 out of 8 sessions in the literature (Liu et al. 2022).), * Women who use mindfulness therapy, laughter therapy or any complementary or integrative medicine in their daily lives outside the research, women who have a diagnosed psychological disease, metastasis or recurrence, and whose chemotherapy treatment was terminated before the study was completed, * Women with stage 3 and stage 4 breast cancer, women who have been receiving chemotherapy for more than 1 year, women whose scores are 8 or below on the Hospital anxiety and depression scale (0-7 points indicate normal, 8-10 points indicate borderline, 11 and above indicate abnormality ).

Inclusion Criteria: * Women and their offspring randomized to vitamin C versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original VCSIP study Exclusion Criteria: * participants who specifically withdraw consent

Inclusion Criteria: * Pregnant women who are planned to give birth at either Holbaek or Nykoebing Falster hospital * Pregnant women diagnosed with periodontitis (stage I-III) by the study dentist Exclusion Criteria: * Pregnant women without peridontitis * Pregnant women with less than 20 healthy teeths * Pregnant women with peridontitis and currently receiving treatment for peridontitis * Pregnant women with peridontitis stage IV